Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Lung Neoplasms 5Myeloproliferative Disorders 4Leukemia, Myelomonocytic, Chronic 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomatitis 2Primary Myelofibrosis 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostate Cancer Metastatic 1Polycythemia Vera 1

Interventions

enzalutamide 3cabazitaxel 3Prednisone 3Docetaxel 2Abiraterone Acetate 2rucaparib 1Zuclomiphene 1XRP6258 1Standard of Care 1LY3023414 1Injections 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Prostate Cancer Metastatic × Injections × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡